Franklin Resources Inc. Buys 8,308 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Franklin Resources Inc. grew its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 3.4% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 252,064 shares of the company’s stock after buying an additional 8,308 shares during the period. Franklin Resources Inc. owned approximately 0.42% of Twist Bioscience worth $11,756,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new stake in Twist Bioscience during the third quarter worth $34,000. Signaturefd LLC lifted its holdings in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares during the period. DekaBank Deutsche Girozentrale bought a new position in shares of Twist Bioscience during the 2nd quarter worth about $61,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in Twist Bioscience by 31.3% in the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after acquiring an additional 546 shares during the period.

Insider Activity

In other Twist Bioscience news, SVP Paula Green sold 3,310 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $143,025.10. Following the transaction, the senior vice president now directly owns 84,585 shares in the company, valued at approximately $3,654,917.85. This represents a 3.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Robert F. Werner sold 1,448 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total transaction of $64,580.80. Following the sale, the chief accounting officer now owns 45,620 shares of the company’s stock, valued at approximately $2,034,652. This represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 99,659 shares of company stock valued at $4,484,602 over the last three months. 3.92% of the stock is owned by insiders.

Analyst Ratings Changes

TWST has been the topic of a number of recent research reports. Wolfe Research assumed coverage on Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. Scotiabank boosted their price target on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. Evercore ISI increased their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird boosted their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, November 19th. Finally, Leerink Partners increased their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average target price of $51.90.

Twist Bioscience Stock Up 9.9 %

Shares of NASDAQ:TWST opened at $47.94 on Friday. The firm has a market cap of $2.85 billion, a P/E ratio of -13.32 and a beta of 1.82. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company’s 50-day moving average price is $45.35 and its two-hundred day moving average price is $46.79.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.